RADX
Income statement / Annual
Last year (2025), Radiopharm Theranostics Ltd's total revenue was $2.71 M,
a decrease of 25.49% from the previous year.
In 2025, Radiopharm Theranostics Ltd's net income was -$53.94 M.
See Radiopharm Theranostics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
| Operating Revenue |
$2.71 M |
$3.63 M |
$299.23 K |
$292.36 K |
$8.83 K |
| Cost of Revenue |
$4.81 M
|
$3.59 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$2.10 M
|
$39.28 K
|
$299.23 K
|
$292.36 K
|
$8.83 K
|
| Gross Profit Ratio |
-0.78
|
0.01
|
1
|
1
|
1
|
| Research and Development Expenses |
$0.00
|
$27.52 M
|
$17.56 M
|
$13.80 M
|
$4.12 M
|
| General & Administrative Expenses |
$0.00
|
$16.53 M
|
$15.22 M
|
$13.02 M
|
$10.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.86 M
|
$16.53 M
|
$15.22 M
|
$13.02 M
|
$10.85 M
|
| Other Expenses |
$48.87 M
|
-$5.83 M
|
$4.14 M
|
$7.98 M
|
$4.95 M
|
| Operating Expenses |
$64.73 M
|
$38.21 M
|
$36.92 M
|
$34.80 M
|
$19.93 M
|
| Cost And Expenses |
$69.54 M
|
$41.81 M
|
$36.92 M
|
$34.80 M
|
$19.93 M
|
| Interest Income |
$0.00
|
$888.20 K
|
$50.48 K
|
$145.04 K
|
$0.00
|
| Interest Expense |
$109.94 K
|
$65.30 K
|
$642.89 K
|
$86.09 K
|
$9.35 M
|
| Depreciation & Amortization |
$0.00
|
$7.33 K
|
$3.13 M
|
$3.30 M
|
$2.98 M
|
| EBITDA |
-$66.84 M |
-$38.17 M |
-$44.08 M |
-$31.19 M |
-$17.96 M |
| EBITDA Ratio |
-24.69
|
-10.5
|
-147.32
|
-106.69
|
-2034.13
|
| Operating Income Ratio |
-24.69
|
-10.51
|
-122.38
|
-118.03
|
-2255.28
|
| Total Other Income/Expenses Net |
$11.18 M
|
-$65.30 K
|
-$11.23 M
|
-$65.10 K
|
-$10.38 M
|
| Income Before Tax |
-$55.65 M
|
-$38.24 M
|
-$47.85 M
|
-$34.57 M
|
-$30.29 M
|
| Income Before Tax Ratio |
-20.56
|
-10.52
|
-159.92
|
-118.26
|
-3430.48
|
| Income Tax Expense |
-$53.25 K
|
$103.29 K
|
$96.36 K
|
$38.01 K
|
$44.40 K
|
| Net Income |
-$53.94 M
|
-$38.34 M
|
-$47.95 M
|
-$34.61 M
|
-$30.34 M
|
| Net Income Ratio |
-19.92
|
-10.55
|
-160.24
|
-118.39
|
-3435.51
|
| EPS |
-4.56 |
-5.28 |
-36 |
-33 |
-29.76 |
| EPS Diluted |
-4.56 |
-5.28 |
-36 |
-33 |
-29.76 |
| Weighted Average Shares Out |
$11.81 M
|
$6.94 M
|
$1.29 M
|
$1.02 M
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$11.81 M
|
$6.94 M
|
$1.29 M
|
$1.02 M
|
$1.02 M
|
| Link |
|
|
|
|
|
